Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

 
• By Aidan Fry
  
PieChart
Coherus believes its Udenyca biosimilar can take at least 20% of the US pegfilgrastim market by the end of this year • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products